International Stem Cell Corporation to Present at Two Upcoming Investor Conferences

CARLSBAD, CA--(Marketwired - May 15, 2013) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies, today announced that it will be presenting at two investor conferences in May. Dr. Simon Craw, Executive Vice President, will present at the B. Riley & Co. 14th Annual Investor Conference in Santa Monica, CA Monday May 20, 2013 and the Marcum LLP 2nd Annual MicroCap Conference in New York City, New York on Thursday, May 30, 2013.

Conference Details:
B. Riley & Co. 14th Annual Investor Conference
Date: Monday, May 20, 2013
Time: 7:30 p.m. Eastern Time / 4:30 p.m. Pacific Time
Location: Loews Santa Monica Beach Hotel, Los Angeles, CA

Marcum LLP 2nd Annual MicroCap Conference
Date: Thursday, May 30, 2013
Time: 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time
Location: Grand Hyatt Hotel, New York, NY

Please contact the conference organizers if you have an interest in attending the conferences or if you would like to arrange a meeting with International Stem Cell Corporation's management team. To register for the event, please visit the conference websites for B. Riley at www.brileyco.com/conference and for Marcum MicroCap Confrerence www.marcumllp.com/microcap.

You may also contact Mark McPartland with MZ Group via email markmcp@mzgroup.us or phone 646.593.7140 to arrange a meeting with management at the conference.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.

To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell